Pazopanib in relapsed osteosarcoma patients: report on 15 cases

References

• Saeter G, Hoie J, Stenwig AE. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995;75:1084–1089.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748–755.
   PubMed Web of Science ®Google Scholar
• Tirtei E, Asaftei SD, Manicone R, et al. Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori. 2017 DOI:10.5301/tj.5000636.
   Web of Science ®Google Scholar
• Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419.
   PubMed Web of Science ®Google Scholar
• Song BS, Seo J, Kim DH, et al. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer. 2014;61:1376.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Jones RL, Paioli A, et al. Gemcitibine (G) and Docetaxel (D) in relapsed and unresectable high grade osteosarcoma after failure of standard multimodal therapy. EMSOS. 2014;(abstr. 7).
   Google Scholar
• Patel S, Vadhan-Raj S, Papadopolous N, et al. High dose Ifosfamide in bone and soft tissue sarcoma: results of the phase II and pilot studies-dose response and schedule dependence. J Clin Oncol. 1997;15:2378–2384.
   PubMed Web of Science ®Google Scholar
• Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24:87–92.
   PubMedGoogle Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.et al EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Lancet. 2012;379:1879–1886.
   PubMed Web of Science ®Google Scholar
• Safwat A, Boysen A, Lücke A, et al. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol. 2014;53:1451–1454.
   PubMed Web of Science ®Google Scholar
• Umeda K, Kato I, Saida S, et al. Pazopanib for second recurrence of osteosarcoma in pediatric patients. Pediatr Int. 2017;59:937–938.
   PubMed Web of Science ®Google Scholar
• Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104:1721–1725.
   PubMed Web of Science ®Google Scholar
• Frakulli R, Salvi F, Balestrini D, et al. Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res. 2015;35:5581–5586.
   PubMed Web of Science ®Google Scholar
• Casanova M, Basso E, Magni C, et al. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma. Tumori. 2017;103:e1–e3.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini Di Leo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–516.
   PubMed Web of Science ®Google Scholar
• Lu X, Xu J, Su X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase 2 clinical trial. J Clin Oncol. 2018;36:(suppl.; abstr. 11520).
   Web of Science ®Google Scholar
• Gaspar N, Casanova M, Sirvent FJB, et al. Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma. J Clin Oncol. 2018;36:(suppl.; abstr. 11527).
   PubMed Web of Science ®Google Scholar
• Duffaud F, Blay JY, Mir O, et al. Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer. J Clin Oncol. 2018;36:(suppl.; abstr. 11504).
   Web of Science ®Google Scholar
• Broto JM, Hindi N, Redondo A. IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—results of the phase I part. J Clin Oncol. 2018;36:(suppl.; abstr. 11515).
   Web of Science ®Google Scholar
• Agulnik M, Mohindra NA, Milhem MM, et al. A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. J Clin Oncol. 2018;36:(suppl.; abstr. 11550).
   PubMed Web of Science ®Google Scholar
• Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer. 2010;67:355–360.
   PubMed Web of Science ®Google Scholar
• Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res. 2014;4:14.
   PubMedGoogle Scholar